Table 5.
Patient characteristics.
| AIM (n = 61) Group A |
AIS (n = 49) Group D |
Control (n = 82) Group K |
Kruskal–Wallis Test p-Value |
|
|---|---|---|---|---|
| Age (y) | 64 | 71 | 64 | 0.001 |
| Sex (m/f) | 41/20 | 23/26 | 39/43 | − |
| Clinical characteristics | ||||
| Arterial hypertension | 35 (57%) | 38 (78%) | 53 (65%) | − |
| Diabetes mellitus | 13 (21%) | 13 (27%) | 11 (13%) | − |
| Current smoker | 36 (59%) | 10 (20%) | 19 (23%) | − |
| BMI | 28.5 | 28.6 | 28.1 | 0.874 |
| Medical history | ||||
| History of MI | 8 (13%) | 5 (10%) | 0 | − |
| History of PCI | 6 (10%) | 2 (4%) | 0 | − |
| History of CABG | 1 (2%) | 3 (6%) | 0 | − |
| History of stroke | 1 (2%) | 0 | 0 | − |
| Laboratory results | ||||
| Creatine (µmol/L) | 78 | 74 | 73 | 0.647 |
| Total cholesterol (mmol/L) | 4.63 | 4.4 | 4.47 | 0.405 |
| TAG (mmol/L) | 1.18 | 1.39 | 1.27 | 0.014 a |
| LDL cholesterol (mmol/L) | 2.88 | 2.59 | 2.52 | 0.008 b |
| HDL cholesterol (mmol/L) | 1.13 | 1.18 | 1.37 | <0.0012 b |
| Pre-procedure hypolidimic treatment | ||||
| Statin | 10 (16%) | 14 (29%) | 31 (38%) | – |
| Fibrate | 1 (2%) | 0 | 1 (1%) | – |
| Ezetimibe | 0 | 0 | 1 (1%) | – |
| Statin + ezetimibe | 0 | 0 | 1 (1%) | – |
| Fibrate + ezetimibe | 0 | 0 | 1 (1%) | – |
| Post-procedure hypolidimic treatment | ||||
| Statin | 60 (98%) | 43 (88%) | NA | – |
| No treatment—patient died | 1 (2%) | 6 (12%) | NA | – |
BMI—body mass index; MI—myocardial infarction; PCI—percutaneous coronary intervention; CABG—coronary artery bypass graft; CKD epi—glomerular filtration; TAG—triacyclglycerols; LDL—low-density lipoprotein; HDL—high-density lipoprotein. Variables are expressed as the median, CI (25%–75%). a Significant in Dunn’s multiple comparisons test, A vs. D. b Significant in Dunn’s multiple comparisons test, A vs. K.